Takeshi Sudo

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi et al. · The Lancet · 2016 · 1.1K citations

Surgical Oncology, Oncology, Pancreatic Cancer +6

Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma

Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo et al. · Annals of Surgical Oncology · 2010 · 236 citations

Prognostic Factors, Surgical Oncology, Surgical Resection +11

Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer

Naru Kondo, Yoshiaki Murakami, Kenichiro Uemura et al. · Annals of Surgical Oncology · 2010 · 168 citations

Prognostic Biomarkers, Surgical Oncology, Prognostic Impact +9

Number of Metastatic Lymph Nodes, but Not Lymph Node Ratio, Is an Independent Prognostic Factor after Resection of Pancreatic Carcinoma

Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo et al. · Journal of the American College of Surgeons · 2010 · 153 citations

Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma

Yoshiaki Murakami, Kenichiro Uemura, Yasuo Hayashidani et al. · Journal of Surgical Oncology · 2007 · 119 citations